Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the treatment of patients with stage III non—small cell lung cancer.

Videos

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the treatment of patients with stage III non-small cell lung cancer (NSCLC).

Dr. Heinzerling on Stage III Treatment of NSCLC

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

There is a lot of work to do in earlier stages of disease, states Heinzerling. As CT screening is being adopted nationwide, more work will need to be done as this is going to shift the patient spectrum from stage IV disease to stage I, II, or III disease.

According to Heinzerling, the hope is there will be early-stage treatments and better cure rates.

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer. 

Dr. Heinzerling on the Development of New Treatments in Early-Stage Lung Cancer

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses remaining challenges for treating stage III non—small cell lung cancer (NSCLC).

Improving efficacy and outcomes for patients with stage III NSCLC is a priority, followed by reducing toxicity.

When chemotherapy is combined with radiation therapy, overall survival, efficacy, and radiation increase. Adding immunotherapy rather than cytotoxic chemotherapy and a change in treatment strategies may help to increase efficacy while decreasing toxicity, explains Heinzerling.

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses remaining challenges for treating stage III non–small cell lung cancer (NSCLC).

Josh H. Heinzerling, MD

Articles

Dr. Heinzerling on Stage III Treatment of NSCLC

Dr. Heinzerling on the Development of New Treatments in Early-Stage Lung Cancer

Dr. Heinzerling on Remaining Challenges for Treating NSCLC